

Arecor Therapeutics

Pipeline and partnership progress plus upcoming catalysts

20 July 2023

- Arecor's H123 business update outlines strong progress across both the in-house and partnered pipelines, and with the roll-out of Ogluo in key European territories. Unaudited cash at end-June 2023 was £8.2m; interim results will report mid-September. H223 is expected to deliver additional AT278 Phase I data, plus potential catalysts in the licenced product portfolio, including an approval decision for the first Arestat-enabled product, AT220, and additional technology partnerships.
- Since IPO, Arecor has secured ten revenue-generating collaborations with major pharma/biotech companies. Two new deals were signed in H123: an additional formulation agreement with an existing top five pharma partner and one with a leading biopharma supporting biosimilar development following an earlier technology partnership. Further deals are expected during H223 and beyond. These agreements provide near-term revenue via research fees, with upside potential from licencing (clinical/commercial milestones and royalties or equivalent).
- Arecor's licenced portfolio also has future milestone and recurring royalty potential. AT220, an undisclosed biosimilar for a multi-billion market, should become the first commercial product incorporating the Arestat technology, with an FDA approval decision pending in H223. The next most advanced asset, Inhibrx's INHBRX-101 is in registration-enabling trials for emphysema due to alpha-1 antitrypsin deficiency (AATD), while a milestone was received on transfer of RTU injectable AT307 to Hikma for further development ([January 2023 Update](#)).
- Clinical progress in the proprietary diabetes portfolio means that the second Phase I study of AT278, ultra-rapid ultra-concentrated insulin, in Type II diabetes patients should complete in Q423. AT278 was designed to address Type II and refractory Type I diabetics that require higher daily dosing and could also facilitate development of next generation miniaturised insulin delivery devices. Data from the second Phase I trial of AT247, ultra-rapid pump-optimised insulin, were presented in June at the ADA (American Diabetes Association) 2023 meeting and showed faster insulin absorption vs current gold standard rapid acting insulins and thus an ideal profile for fully closed loop "artificial pancreas" pumps.

Price	205p
Market Cap	£68.76m
Primary exchange	AIM
Sector	Healthcare
Company Code	AREC
Corporate client	Yes

Company description:

Arecor Therapeutics is a revenue-generating clinical stage drug developer, with a well-balanced portfolio of in-house and partnered programmes. Its proprietary Arestat formulation platforms result in enhanced products with lower development risks and less onerous regulatory approvals.

Trinity Delta view: Arecor continues to advance across its multi-faceted business as it builds a self-sustaining biopharma company. Demonstrable clinical progress with its Diabetes and Specialty Hospital pipeline and growing revenue potential from existing (and future) partnerships as well as from its commercial arm, Tetris Pharma, all contribute momentum. Data, regulatory decisions, and business development activity are expected in H223; the latter demonstrating the applicability of the proprietary Arestat platforms in developing novel and differentiated formulations of existing drugs with enhanced properties. We value Arecor, using conservative assumptions, at £176m, or 575p per share.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2023 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org